APPLICATION
ANDA077046
TYPE
ANDA
ORIGINAL APPROVAL
2004-11-24
LATEST ACTION
2024-06-03
ROUTE
ORAL
DOSAGE FORM
TABLET
MARKETING STATUS
Discontinued
Products
CITALOPRAM HYDROBROMIDEDiscontinued
CITALOPRAM HYDROBROMIDE EQ 20MG BASE · TABLET · ORAL
CITALOPRAM HYDROBROMIDEDiscontinued
CITALOPRAM HYDROBROMIDE EQ 40MG BASE · TABLET · ORAL
CITALOPRAM HYDROBROMIDEDiscontinued
CITALOPRAM HYDROBROMIDE EQ 10MG BASE · TABLET · ORAL
Approval history
2024-06-03Labeling · Supplement 24 · standardAP
2022-10-05Labeling · Supplement 21 · standardAP
2022-10-05Labeling · Supplement 22 · standardAP
2022-10-05Labeling · Supplement 20 · standardAP
2022-10-05Labeling · Supplement 19 · standardAP
2016-07-27Labeling · Supplement 18 · standardAP
2014-12-05Labeling · Supplement 17 · standardAP
2012-04-25Labeling · Supplement 14AP
2009-06-17Labeling · Supplement 11AP
2009-06-17Labeling · Supplement 12AP
2008-12-17Labeling · Supplement 10AP
2007-06-28Labeling · Supplement 8AP
2006-03-24Labeling · Supplement 3AP
2005-08-26Labeling · Supplement 5AP
2005-04-29Labeling · Supplement 4AP
Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.
Weekly Briefing
Read a past issue →Get the Weekly GxP Briefing
Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.